Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RINGSIDE AL102 in progressing desmoid tumors
NL-OMON56437Phase 3Recruiting
- Sponsor
- Immunome
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of varegacestat in aggressive fibromatosis (AF) (6 arms), sponsored by Immunome. Primary endpoints: Frequency and severity of TEAEs and SAEs, Time to treatment discontinuation due to TEAE and 1 more. Started Feb 2022; status: recruiting.
02
Drugs
varegacestat
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on NL-OMON56437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56437.